摘要
Structural biology and functional studies are a powerful combination to elucidate fundamental knowledge about the cystic fibrosis transmembrane conductance regulator (CFTR). Here, we discuss the latest findings, including how clinically-approved drugs restore function to mutant CFTR, leading to better clinical outcomes for people with cystic fibrosis (CF). Despite the prospect of regulatory approval of a CFTR-targeting therapy for most CF mutations, strenuous efforts are still needed to fully comprehend CFTR structure-and-function for the development of better drugs to enable people with CF to live full and active lives.
原文 | English |
---|---|
頁(從 - 到) | S19-S24 |
期刊 | Journal of Cystic Fibrosis |
卷 | 19 |
DOIs | |
出版狀態 | Published - 3月 2020 |